<DOC>
	<DOC>NCT01884272</DOC>
	<brief_summary>This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.</brief_summary>
	<brief_title>NSAID Drug Interaction Study</brief_title>
	<detailed_description>Naproxen and indomethacin are non-steroidal anti-inflammatory drugs (NSAIDs) used both prophylactically for the prevention of, and as a treatment for, acute gout flares. RDEA594-126 is an open-label study designed to assess the potential effect of multiple doses of naproxen and indomethacin on the single-dose PK of lesinurad, and to assess the potential effect of multiple doses of lesinurad on the multiple-dose PK of naproxen and indomethacin.</detailed_description>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Subject has a body weight ≥ 50 kg (110 lbs) and a body mass index (BMI) ≥ 18 and ≤ 30 kg/m2. Subject is free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures. Subject has no clinically relevant abnormalities in vital signs, ECG, physical examination or safety laboratory values. Subject has clinically significant pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders. Subject has a history or suspicion of kidney stones. Subject has a history of asthma. Subject has undergone major surgery within 3 months prior to Day 1. Subject has donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening visit. Subject has inadequate venous access or unsuitable veins for repeated venipuncture.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>